OTS -Rentschler and Leukocare announce strategic alliance and equity investment
2017. February 06. 15:39
Laupheim and Munich/Martinsried, Germany, 2 February
2017.,(APA/OTS) - Rentschler Biotechnologie GmbH, Laupheim and
Leukocare AG, Martinsried today announced a strategic alliance
under which Leukocare will become the specialized technology
partner and the exclusive formulation developer for Rentschler's
biopharmaceuticals business. Rentschler in return will become the
first and only contract development and manufacturing organization
(CDMO) to have access to Leukocare´s patented SPS® formulation
technologies. Leukocare's ongoing and future business activities
with pharma and biotech beyond the CDMO business will not be
affected by this alliance. Rentschler will acquire a 10% stake in
Leukocare. Dr. Frank Mathias, CEO of Rentschler, will join
Leukocare's Board of Directors.
Rentschler is a German family-owned business and among the
world´s leading biopharmaceutical CDMOs. The company has a long
track record of delivering successful consulting, bioprocess
development and manufacturing solutions for market-ready
biopharmaceutical products, all from one source.
Leukocare provides formulation development services based on
its proprietary SPS® (Stabilizing and Protecting Solutions)
technology platform, which has been shown to significantly improve
the stability of therapeutic proteins. Based on SPS®, Leukocare is
able to develop, for example, liquid dose formulations that result
in biopharmaceuticals with outstanding stability at higher
temperatures and longer shelf life. The patented SPS® platform is
characterized by specific and innovative combinations of regulatory
established and employed excipients.
Creating competitive advantages for clients with best-in-class
formulations
The Rentschler/Leukocare alliance strategically aims to
incorporate formulation development at every step throughout
biopharmaceutical development and manufacturing. Working closely
with the client, this will ensure that every end product will -
from the very beginning - have a best-in-class formulation and
administration mode. This innovative approach will provide clients
significant competitive advantages, enabling them to exploit the
full potential of their products and markets.
"Our alliance brings to the forefront the importance of drug
formulation as a key success factor in the development process. We
believe our enhanced ability to improve formulations will result in
value creation for our clients and ultimately also help doctors and
patients," said Dr. Frank Mathias, CEO of Rentschler.
"This alliance will enable us to fully exploit the
possibilities and advantages of the SPS® formulation technologies,"
stated Michael Scholl, CEO of Leukocare. "With a strong partner
like Rentschler, we will be able to offer our innovative
formulation expertise to a broad range of clients and elevate the
role of formulation strategy on the biopharmaceutical industry's
agenda."
About Rentschler Biotechnologie GmbH
Rentschler Biotechnologie GmbH, located in Laupheim, Germany,
is a leading contract development and manufacturing organization
(CDMO) for bioprocess development and manufacturing of
biopharmaceuticals as well as for regulatory support. The Company's
clients include innovative biotech companies and major
pharmaceutical companies around the world. Many years of experience
and excellence in finding solutions as well as certified quality
management and advanced technologies ensure Rentschler's high
quality standards. Rentschler is a family-owned company employing
approximately 700 people. For further information, please visit
www.rentschler.de.
About LEUKOCARE AG
LEUKOCARE AG, located in Martinsried, Germany, provides a
next-generation formulation platform for the protection of proteins
like biopharmaceuticals to allow the development of better
products. The proprietary SPS® technologies are provided to
development projects of partners in the pharmaceutical and medical
device industry. LEUKOCARE's SPS® technologies improve stability
and quality of biologics like antibodies, vaccines, etc. in dry and
liquid formulation. SPS® also protects proteins in biologically
functionalized combination devices. For further information please
visit www.leukocare.com.
About the Rentschler and Leukocare alliance
The alliance between Rentschler Biotechnologie GmbH and
Leukocare AG strategically aims to incorporate formulation
development at every step throughout biopharmaceutical development
and manufacturing. Working closely with the client, this will
ensure that the end products will - from the very beginning - have
a best-in-class formulation and administration mode. This
innovative approach will provide clients significant competitive
advantages, enabling them to exploit the full potential of their
products and markets.
Contact
Raimund Gabriel
Managing Partner
MC Services AG
Phone: +49-89-210228-36
Email: rentschler-leukocare@mc-services.eu
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.